Marshall Wace LLP Acquires New Shares in Rezolute, Inc. (NASDAQ:RZLT)

Marshall Wace LLP bought a new position in Rezolute, Inc. (NASDAQ:RZLT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,047,230 shares of the company’s stock, valued at approximately $4,503,000. Marshall Wace LLP owned 2.61% of Rezolute at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in RZLT. Virtu Financial LLC bought a new position in shares of Rezolute during the first quarter worth about $37,000. Jeppson Wealth Management LLC bought a new position in Rezolute in the 2nd quarter worth about $45,000. XTX Topco Ltd grew its position in Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Rezolute in the first quarter valued at approximately $229,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Rezolute during the second quarter valued at approximately $255,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Price Performance

Shares of RZLT opened at $4.59 on Wednesday. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The stock has a market capitalization of $184.22 million, a P/E ratio of -4.03 and a beta of 1.18. The firm’s 50 day moving average is $4.64 and its 200-day moving average is $3.89.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). As a group, equities research analysts forecast that Rezolute, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Maxim Group raised their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. Craig Hallum began coverage on Rezolute in a report on Tuesday, June 4th. They set a “buy” rating and a $14.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Guggenheim initiated coverage on shares of Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a report on Friday, September 27th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.